S1PR5 and multiple sclerosis: Accordingly, we asked whether the effects of FTY720 could be mimicked by ozanimod, S1P1 and S1P5 agonist just clinically approved for multiple sclerosis [11] and currently under clinical investigation for IBDs [3].